This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Plasma Proteomics Analysis for Screening Anlotinib Responders in Non-small Cell Lung Cancer
Baohui Han
Shanghai Jiao Tong University Affiliated Chest Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3950-3030
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. The underlying value of proteomics for anlotinib study remains unclear.
Methods
In this study, plasma samples from 28 anlotinib-treated NSCLC patients (including 14 responders and 14 non-responders) were performed proteomics analysis. LC-MS/MS analysis was performed on those samples with different time points including baseline, best response and progression disease. Bioinformatics analysis was performed to understand the underlying value of those differential proteins.
Results
Proteomics analysis suggested the differential proteins from responders after anlotinib administration potential play a role in the molecular mechanism characterization and biomarker screening. The differential proteins between responders and non-responders at baseline mainly contribute to biomarker screening. Integrative analysis indicated 43 proteins could be used as underlying biomarkers for clinical practice. Lastly, we selected ARHGDIB and demonstrated that it has potential predictive value for anlotinib.
Conclusions
This study not only offered the first insight that the proteomic technology potentially be used for anlotinib molecular mechanism characterization, but also provided a basis for anlotinb biomarker screening via proteomics in the future.
Keywords
Proteomics, Anlotinib, Biomarker, Non-small cell lung cancer, liquid biopsy
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 12 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Informatics
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Plasma Proteomics Analysis for Screening Anlotinib Responders in Non-small Cell Lung Cancer
Baohui Han
Shanghai Jiao Tong University Affiliated Chest Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3950-3030
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 12 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Informatics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. The underlying value of proteomics for anlotinib study remains unclear.
Methods
In this study, plasma samples from 28 anlotinib-treated NSCLC patients (including 14 responders and 14 non-responders) were performed proteomics analysis. LC-MS/MS analysis was performed on those samples with different time points including baseline, best response and progression disease. Bioinformatics analysis was performed to understand the underlying value of those differential proteins.
Results
Proteomics analysis suggested the differential proteins from responders after anlotinib administration potential play a role in the molecular mechanism characterization and biomarker screening. The differential proteins between responders and non-responders at baseline mainly contribute to biomarker screening. Integrative analysis indicated 43 proteins could be used as underlying biomarkers for clinical practice. Lastly, we selected ARHGDIB and demonstrated that it has potential predictive value for anlotinib.
Conclusions
This study not only offered the first insight that the proteomic technology potentially be used for anlotinib molecular mechanism characterization, but also provided a basis for anlotinb biomarker screening via proteomics in the future.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6